More Life Company Partnered With U.S. Compounding Pharmacy

The firm aims to scale its Quicksome delivery technology through a new U.S. pharmacy partnership.

Updated on Oct. 6, 2026 in Healthcare

Isometric editorial illustration of a stainless-steel centrifuge and clear glass vials, representing pharmaceutical infrastructure and technology integration. — The More Life Company has signed a partnership with a U.S. compounding pharmacy to scale its proprietary delivery technology for specialized pharmaceutical products. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies use compounding pharmacies to accelerate the commercialization of new drug delivery technologies?

The More Life Company Corp. has signed a non-binding letter of intent with an unnamed U.S. 503A compounding pharmacy. The agreement focuses on the development and commercialization of pharmaceutical products utilizing the firm’s Quicksome delivery technology.

Why it matters

This partnership seeks to establish dedicated U.S. infrastructure for compounding and fulfilling prescription products, allowing the firm to bypass traditional development hurdles. It positions the company to accelerate market entry for specialized treatments like hormone replacement and peptides.

The agreement secures a 503A-classified compounding pharmacy partner to manage fulfillment infrastructure. While the deal is currently non-binding, the firm is shifting focus toward executing definitive documentation and scaling its proprietary delivery platform.

The players

The More Life Company Corp.

A Toronto-based biotechnology firm focused on developing proprietary drug delivery technologies for the pharmaceutical market.

The details

The partnership integrates the firm's proprietary Quicksome formulation technology directly into the partner's existing pharmacy and fulfillment workflows. By utilizing a 503A pharmacy model, the parties aim to address specific compounding requirements for products like CoQ10, peptides, and testosterone. The companies are currently finalizing operational readiness and compounding implementation plans.

October 6, 2026: The More Life Company Corp. announced the signing of the letter of intent.

Market Landscape

This deal leverages the 503A compounding framework established by the Federal Food, Drug, and Cosmetic Act to facilitate product commercialization. It follows an industry trend where biotech firms prioritize partnerships with established pharmacy infrastructure to bypass the regulatory burden of traditional drug manufacturing.

Operators in the pharmacy and telehealth sectors should monitor the firm’s progress in securing definitive documentation with its partner. The transition to commercialization for Quicksome-enabled products may open new supply chain avenues for specialized wellness and prescription treatments.

The takeaway

The firm is moving to operationalize its formulation technology by securing a domestic pharmacy footprint. Keep a close watch on the subsequent execution of definitive documentation, which will signal the official transition from development to active commercial distribution.